Tags : E2609

Eisai And Biogen to Terminate Two P-III Clinical Studies of

Tuba Khan September 13, 2019

Shots: The two P-III MISSION AD1 and MISSION AD2 studies involves assessing of Elenbecestat (50mg) vs PBO in 2,100 patients with mild cognitive impairment or mild AD with confirmed amyloid […]readmore

Tags : E2609

Eisai And Biogen to Terminate Two P-III Clinical Studies of

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : E2609

Eisai And Biogen to Terminate Two P-III Clinical Studies of

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company